Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Prostate Advances in Comparative Evidence (PACE)

This study has been terminated.
(Study sponsorship has transitioned to the Royal Marsden (UK).)
Sponsor:
Collaborators:
Royal Marsden NHS Foundation Trust, London, UK
Mount Vernon Cancer Center, East & North Herts NHS Trust,Northwood,Middlesex, UK
Centre Oscar Lambret, Lille, France
Charite University, Berlin, Germany
Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
The Institute of Cancer Research, Sutton, Surrey, UK
Information provided by (Responsible Party):
Accuray Incorporated
ClinicalTrials.gov Identifier:
NCT01584258
First received: April 22, 2012
Last updated: June 23, 2014
Last verified: June 2014

April 22, 2012
June 23, 2014
April 2012
June 2014   (final data collection date for primary outcome measure)
Biochemical disease-free survival [ Time Frame: 5 years (primary timepoint) ] [ Designated as safety issue: No ]

Biochemical progression is defined as follows: For conventional radiation and radiosurgery arms: Serum PSA of at least 2 ng/mL greater than the post-radiotherapy nadir (lowest PSA to date)(Phoenix definition); for surgical arm: PSA > 0.2 ng/mL.

For either arm, a recommencement of androgen deprivation also counts as biochemical failure.

Same as current
Complete list of historical versions of study NCT01584258 on ClinicalTrials.gov Archive Site
  • Cause-specific and overall survival [ Time Frame: 10 years ] [ Designated as safety issue: No ]
    Cause-specific survival will include deaths from prostate cancer only. Overall survival will include deaths from any cause.
  • Progression-free survival [ Time Frame: 10 years ] [ Designated as safety issue: No ]
    Radiographic or clinical evidence of local, regional or distant failure.
  • Toxicities associated with surgery, radiotherapy and radiosurgery [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
    Assessed by CTCAE version 4
  • Quality of Life [ Time Frame: 10 years ] [ Designated as safety issue: No ]
    Using EORTC Quality of Life Questionnaire PR-25
Same as current
Not Provided
Not Provided
 
Prostate Advances in Comparative Evidence
International Randomized Study of Laparoscopic Prostatectomy vs Radiosurgery and Conventionally Fractionated Radiotherapy vs Radiosurgery for Early Stage Organ-Confined Prostate Cancer

This study is an international multicenter randomized study of organ confined low and intermediate risk prostate cancer and is composed of two parallel randomization schemes based on applicability of surgery as a treatment for the patient. Patients for whom surgery is a consideration are randomized to either laparoscopic or da Vinci prostatectomy or CyberKnife prostate SBRT(also known as CyberKnife radiosurgery). Patients for whom surgery is not a consideration are randomized to either conventionally fractionated radiation therapy or CyberKnife prostate SBRT. Efficacy, toxicity and quality of life outcomes will be compared across the pairs in each randomization.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostate Cancer
Other: CyberKnife prostate SBRT delivered by the CyberKnife in 36.25Gy in 5 fractions or 38Gy in 4 fractions
CyberKnife prostate SBRT delivered by the CyberKnife in 36.25Gy in 5 fractions or 38Gy in 4 fractions.
  • Active Comparator: Laparoscopic prostatectomy vs CyberKnife prostate SBRT
    Patients for whom surgery is considered will be randomized to laparoscopic prostatectomy (manual laparoscopic prostatectomy or da Vinci prostatectomy) or CyberKnife prostate SBRT.
    Intervention: Other: CyberKnife prostate SBRT delivered by the CyberKnife in 36.25Gy in 5 fractions or 38Gy in 4 fractions
  • Active Comparator: Conventionally fractionated RT vs CyberKnife prostate SBRT
    Patients for whom surgery is not considered or who refuse surgery will be randomized to either conventionally fractionated radiotherapy or CyberKnife SBRT.
    Intervention: Other: CyberKnife prostate SBRT delivered by the CyberKnife in 36.25Gy in 5 fractions or 38Gy in 4 fractions
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
136
June 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histological confirmation of prostate adenocarcinoma with a minimum of 10 biopsy cores taken.
  • Gleason score ≤ 3+4
  • Men aged ≥18
  • Clinical and MRI stage T1c -T2c, N0-X, M0-X
  • PSA ≤ 20 ng/mL
  • Pre-enrollment PSA must be completed within 60 days of registration
  • Patients belonging in one of the following risk groups according to the National Comprehensive Cancer Network:

    • Low risk: Clinical stage T1-T2a and Gleason ≤ 6 and PSA < 10 ng/ml, or
    • Intermediate risk includes any one of the following:

      • Clinical stage T2b or T2c
      • PSA 10-20 ng/ml or
      • Gleason 7
  • WHO performance status 0 - 2
  • Prostate volume ≤ 90 cc
  • Ability of the research subject or authorized legal representative to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Clinical stage T3 or greater
  • Gleason score ≥ 4 + 3
  • < 10 prostate biopsies taken
  • High risk disease as defined by National Comprehensive Cancer Network (www.nccn.org)
  • Previous malignancy within last 5 years except basal cell carcinoma or squamous cell carcinoma of the skin
  • Prior pelvic radiotherapy
  • Prior androgen deprivation therapy (including androgen agonists and antagonists)
  • Any prior active treatment for prostate cancer
  • Life expectancy <10 years
  • Bilateral hip prostheses or any other implants/hardware that would introduce substantial CT artifacts
  • Medical conditions likely to make radiotherapy inadvisable eg inflammatory bowel disease, significant urinary symptoms
  • Anticoagulation with warfarin or bleeding tendency making fiducial placement unsafe.
  • Medical condition/ implant that prohibits MRI
  • Comorbidity that excludes surgery (patients can still be entered into radiotherapy randomization arm)
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT01584258
ACCP003
Yes
Accuray Incorporated
Accuray Incorporated
  • Royal Marsden NHS Foundation Trust, London, UK
  • Mount Vernon Cancer Center, East & North Herts NHS Trust,Northwood,Middlesex, UK
  • Centre Oscar Lambret, Lille, France
  • Charite University, Berlin, Germany
  • Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
  • The Institute of Cancer Research, Sutton, Surrey, UK
Principal Investigator: Nicholas van As, MD Royal Marsden NHS Foundation Trust, London, United Kingdom
Study Chair: Shafak Aluwini, MD Erasmus MC, Rotterdam, the Netherlands
Study Chair: Volker Budach, MD Charité - Universitätsmedizin Berlin, Germany
Study Chair: Luca Incrocci, MD Erasmus MC, Rotterdam, the Netherlands
Study Chair: Eric Lartigau, MD Centre Oscar Lambret, Lille, France
Study Chair: Peter Ostler, MD Mount Vernon Cancer Centre, United Kingdom
Study Chair: Alan Thompson, MD Royal Marsden NHS Foundation Trust, London, United Kingdom
Accuray Incorporated
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP